New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Profit margins are more than 30% lower than last year (6.5% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩4,540, the stock trades at a trailing P/E ratio of 65.2x. Average trailing P/E is 15x in the Life Sciences industry in South Korea. Total returns to shareholders of 10% over the past three years. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩3,710, the stock trades at a trailing P/E ratio of 53.3x. Average trailing P/E is 16x in the Life Sciences industry in South Korea. Total loss to shareholders of 20% over the past three years. New Risk • Jun 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩155.8b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (6.5% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (₩155.8b market cap, or US$99.9m). Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩4,600, the stock trades at a trailing P/E ratio of 66x. Average trailing P/E is 20x in the Life Sciences industry in South Korea. Total loss to shareholders of 8.9% over the past three years. New Risk • Apr 01
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.1% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Annuncio • Mar 17
NanoEntek, Inc., Annual General Meeting, Mar 31, 2026 NanoEntek, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 28% After last week's 28% share price decline to ₩5,360, the stock trades at a trailing P/E ratio of 76.2x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total loss to shareholders of 14% over the past three years. New Risk • Feb 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding). Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩5,440, the stock trades at a trailing P/E ratio of 77.3x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 4.6% over the past three years. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩3,995, the stock trades at a trailing P/E ratio of 56.8x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 21% over the past three years. New Risk • Oct 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (₩125.9b market cap, or US$87.6m). New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩112.7b market cap, or US$81.3m). Annuncio • Jun 12
NanoEntek, Inc. (KOSDAQ:A039860) agreed to acquire AAI Health Care Co., Ltd. for KRW 22.7 billion. NanoEntek, Inc. (KOSDAQ:A039860) agreed to acquire AAI Health Care Co., Ltd. for KRW 22.7 billion on June 11, 2025. The consideration consists of 6.27 million common equity of NanoEntek, Inc. to be issued for common equity of AAI Health Care Co., Ltd. As of the stock exchange date, the AAI Health Care Co., Ltd. stocks owned by shareholders of AIAI Healthcare Co., Ltd. are transferred to NanoEntek, Inc., and in return, 0.4748121 shares of NanoEntek, Inc. common stock are exchanged and paid to the target shareholders for each share of AAI Health Care Co., Ltd. common stock.
The expected completion of the transaction is October 1, 2025. Reported Earnings • Mar 22
Full year 2024 earnings released: EPS: ₩119 (vs ₩137 loss in FY 2023) Full year 2024 results: EPS: ₩119 (up from ₩137 loss in FY 2023). Revenue: ₩30.5b (up 14% from FY 2023). Net income: ₩3.59b (up ₩7.26b from FY 2023). Profit margin: 12% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance. Annuncio • Mar 12
NanoEntek, Inc., Annual General Meeting, Mar 26, 2025 NanoEntek, Inc., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩109.0b market cap, or US$75.9m). New Risk • Dec 07
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩99.5b market cap, or US$70.0m). New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩101.9b market cap, or US$77.5m). New Risk • Aug 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 27% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Jun 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩107.6b market cap, or US$78.0m). Reported Earnings • Mar 22
Full year 2023 earnings released: ₩137 loss per share (vs ₩174 profit in FY 2022) Full year 2023 results: ₩137 loss per share (down from ₩174 profit in FY 2022). Revenue: ₩26.8b (down 24% from FY 2022). Net loss: ₩3.68b (down 179% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩125.2b market cap, or US$93.8m). New Risk • Nov 21
New major risk - Revenue and earnings growth Earnings have declined by 7.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩98.7b market cap, or US$76.3m). Board Change • Oct 12
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Vice-President and Director Jung-Goo Seo was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₩5,240, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total loss to shareholders of 51% over the past three years. New Risk • Jun 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩127.9b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (7.9% net profit margin). Market cap is less than US$100m (₩127.9b market cap, or US$98.9m). Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩5,100, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 20x in the Life Sciences industry in South Korea. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 36% share price gain to ₩6,790, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 20x in the Life Sciences industry in South Korea. Total returns to shareholders of 23% over the past three years. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Vice-President and Director Jung-Goo Seo was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Buying Opportunity • Oct 11
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be ₩6,218, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%. Buying Opportunity • Sep 22
Now 22% undervalued Over the last 90 days, the stock is up 15%. The fair value is estimated to be ₩6,834, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improved over the past week After last week's 30% share price gain to ₩6,390, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 22x in the Life Sciences industry in South Korea. Total returns to shareholders of 43% over the past three years. Buying Opportunity • Jul 21
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be ₩7,438, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 17%. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 17% share price gain to ₩5,420, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩5,140, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.7% over the past three years. Buying Opportunity • Jun 13
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be ₩7,364, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 17%. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Vice-President and Director Jung-Goo Seo was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 33% share price gain to ₩8,470, the stock trades at a trailing P/E ratio of 31x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 64% over the past three years. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩6,910, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Total returns to shareholders of 32% over the past three years. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improved over the past week After last week's 18% share price gain to ₩8,010, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 24x in the Life Sciences industry in South Korea. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩6,190, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 9.2% over the past three years. Valuation Update With 7 Day Price Move • May 04
Investor sentiment deteriorated over the past week After last week's 20% share price decline to ₩9,080, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 74x in the Life Sciences industry in South Korea. Total returns to shareholders of 57% over the past three years. Is New 90 Day High Low • Feb 26
New 90-day low: ₩7,390 The company is down 16% from its price of ₩8,770 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 3.0% over the same period. Is New 90 Day High Low • Jan 14
New 90-day low: ₩7,910 The company is down 27% from its price of ₩10,900 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: ₩8,270 The company is down 26% from its price of ₩11,250 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 16% over the same period. Is New 90 Day High Low • Nov 24
New 90-day low: ₩8,890 The company is down 22% from its price of ₩11,350 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period. Valuation Update With 7 Day Price Move • Oct 26
Market pulls back on stock over the past week After last week's 16% share price decline to ₩8,900, the stock is trading at a trailing P/E ratio of 42.4x, down from the previous P/E ratio of 50.7x. This compares to an average P/E of 86x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 73%. Is New 90 Day High Low • Oct 22
New 90-day low: ₩10,000 The company is down 6.0% from its price of ₩10,650 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 8.0% over the same period. 
